How to buy Proteostasis Therapeutics stock

Proteostasis Therapeutics, Inc is a biotechnology business based in the US. Proteostasis Therapeutics shares (PTI) are listed on the NASDAQ and all prices are listed in US Dollars. Proteostasis Therapeutics employs 44 staff and has a market cap (total outstanding shares value) of USD$56.4 million.

How to buy shares in Proteostasis Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Proteostasis Therapeutics. Find the stock by name or ticker symbol: PTI. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Proteostasis Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Proteostasis Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Proteostasis Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Proteostasis Therapeutics share price

Use our graph to track the performance of PTI stocks over time.

Proteostasis Therapeutics shares at a glance

• Key figures

Information last updated 2020-11-19.

52-week range	USD$0.87 - USD$4.72
50-day moving average	USD$1.1044
200-day moving average	USD$1.3353
Wall St. target price	USD$4.67
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.504

Buy Proteostasis Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Proteostasis Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Proteostasis Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Proteostasis Therapeutics financials

Gross profit TTM	USD$5 million
Return on assets TTM	-31.16%
Return on equity TTM	-72.38%
Profit margin	0%
Book value	$0.711
Market capitalisation	USD$56.4 million

TTM: trailing 12 months

Shorting Proteostasis Therapeutics shares

There are currently 1.4 million Proteostasis Therapeutics shares held short by investors – that's known as Proteostasis Therapeutics's "short interest". This figure is 0.9% up from 1.4 million last month.

There are a few different ways that this level of interest in shorting Proteostasis Therapeutics shares can be evaluated.

Proteostasis Therapeutics's "short interest ratio" (SIR)

Proteostasis Therapeutics's "short interest ratio" (SIR) is the quantity of Proteostasis Therapeutics shares currently shorted divided by the average quantity of Proteostasis Therapeutics shares traded daily (recently around 370975.066313). Proteostasis Therapeutics's SIR currently stands at 3.77. In other words for every 100,000 Proteostasis Therapeutics shares traded daily on the market, roughly 3770 shares are currently held short.

However Proteostasis Therapeutics's short interest can also be evaluated against the total number of Proteostasis Therapeutics shares, or, against the total number of tradable Proteostasis Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Proteostasis Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Proteostasis Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0271% of the tradable shares (for every 100,000 tradable Proteostasis Therapeutics shares, roughly 27 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Proteostasis Therapeutics.

Find out more about how you can short Proteostasis Therapeutics stock.

Proteostasis Therapeutics share dividends

We're not expecting Proteostasis Therapeutics to pay a dividend over the next 12 months.

Proteostasis Therapeutics share price volatility

Over the last 12 months, Proteostasis Therapeutics's shares have ranged in value from as little as $0.87 up to $4.72. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Proteostasis Therapeutics's is 1.1851. This would suggest that Proteostasis Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Proteostasis Therapeutics overview

Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.

Frequently asked questions

• What percentage of Proteostasis Therapeutics is owned by insiders or institutions?

  Currently 15.299% of Proteostasis Therapeutics shares are held by insiders and 22.12% by institutions.

• How many people work for Proteostasis Therapeutics?

  Latest data suggests 44 work at Proteostasis Therapeutics.

• When does the fiscal year end for Proteostasis Therapeutics?

  Proteostasis Therapeutics's fiscal year ends in December.

• Where is Proteostasis Therapeutics based?

  Proteostasis Therapeutics's address is: 80 Guest Street, Boston, MA, United States, 02135

• What is Proteostasis Therapeutics's ISIN number?

  Proteostasis Therapeutics's international securities identification number is: US74373B1098

• What is Proteostasis Therapeutics's CUSIP number?

  Proteostasis Therapeutics's Committee on Uniform Securities Identification Procedures number is: 74373B109